Avid Bioservices Inc (CDMO)

[cjgaddy]

6-28-07: Rodman&Renshaw Arranges $22.5mm Direct Placement

Peregrine Pharmaceuticals Announces Registered Direct Offering of $22.5 Million in Common Stock
http://www.peregrineinc.com/content.php?mi=MTc=&appAction=--PRINT&Id=MTAyMTMwOQ

TUSTIN, CA, June 28 2007: Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has obtained commitments from several institutional investors to purchase approximately $22.5 million in shares of its common stock in a registered direct offering.

Under the terms of the transaction, Peregrine will receive approximately $22.5 million in gross proceeds in exchange for up to 30,000,000 shares of its common stock. Net proceeds following the payment of sales commissions and other expenses of the offering are expected to be approximately $20.9 million. Rodman & Renshaw, LLC acted as the exclusive placement agent in connection with this transaction. The offering is expected to close on or about July 3, 2007, subject to the satisfaction of certain closing conditions.

Peregrine intends to use the net proceeds to fund its research and development programs and related costs, primarily for conducting clinical trials of bavituximab for the treatment of cancer and hepatitis C virus infection. The company plans to initiate several Phase II studies evaluating bavituximab in combination with chemotherapy for the treatment of solid cancers, to conduct clinical studies evaluating bavituximab for the treatment of chronic HCV infection, including in patients co-infected with HCV and HIV, and to complete an ongoing Phase II study of Cotara(R) for the treatment of glioblastoma multiforme. The company also intends to use the proceeds to further strengthen its product and business development infrastructure, and for other general corporate purposes.

A shelf registration statement relating to the common stock to be issued in the offering has been filed with the Securities and Exchange Commission and became effective as of January 23, 2007. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Rodman & Renshaw, LLC, 1270 Avenue of the Americas, 28th Floor, New York, NY 10020, Fax: [phone]. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing 3 separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.
Safe Harbor *snip*

Contacts: GendeLLindheim BioCom Partners
Investors: 800-987-8256, [e-mail]
Media: Barbara Lindheim, 212-918-4650
*end*

= = = = = = = = = = =
Rodman & Renshaw, LLC is a privately-held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support.
http://www.rodmanandrenshaw.com

FOCUS AREAS: HEALTHCARE & TECHNOLOGY
Healthcare: As the field of biotechnology continues to grow in both size and stature, we at Rodman seek to identify the innovators and leaders in this expanding sector…

HEALTHCARE COVERAGE UNIVERSE:
http://www.rodmanandrenshaw.com/rodman.asp?link=universelife

INVESTMENT-BANKING:
“Emerging growth companies succeed by creating innovative products and services, by being better and faster than the competition, by recognizing opportunities where others see only risks.”
http://www.rodmanandrenshaw.com/rodman.asp?link=investbank